|
PLA2G12A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.66830000036811E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.54019999998312E-06 |
| Normal-vs-Stage2 |
2.559200E-01 |
| Normal-vs-Stage3 |
1.11079999642882E-08 |
| Normal-vs-Stage4 |
6.45100000085108E-08 |
| Stage1-vs-Stage2 |
3.782500E-03 |
| Stage1-vs-Stage3 |
1.744220E-02 |
| Stage1-vs-Stage4 |
2.624100E-02 |
| Stage2-vs-Stage3 |
5.75990000000193E-05 |
| Stage2-vs-Stage4 |
1.361730E-04 |
| Stage3-vs-Stage4 |
7.134800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.15050002647399E-09 |
| Normal-vs-AfricanAmerican |
3.757200E-03 |
| Normal-vs-Asian |
1.71525999999034E-05 |
| Caucasian-vs-AfricanAmerican |
6.795200E-01 |
| Caucasian-vs-Asian |
7.202400E-01 |
| AfricanAmerican-vs-Asian |
5.513800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.32160000054782E-07 |
| Normal-vs-Female |
1.56049999999741E-06 |
| Male-vs-Female |
1.462800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.94930000002791E-06 |
| Normal-vs-Age(41-60Yrs) |
1.20359999966624E-07 |
| Normal-vs-Age(61-80Yrs) |
1.183920E-04 |
| Normal-vs-Age(81-100Yrs) |
2.034200E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.779600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.077600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.694000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.064600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.277600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.686200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.647900E-04 |
| Classical-VS-Follicular |
2.861500E-03 |
| Classical-VS-Other |
6.742000E-01 |
| Classical-VS-Normal |
1.0946999995376E-07 |
| Tall-VS-Follicular |
4.12250000025871E-07 |
| Tall-VS-Other |
2.221200E-01 |
| Tall-VS-Normal |
2.34109998054066E-09 |
| Follicular-VS-Other |
1.983010E-01 |
| Follicular-VS-Normal |
7.944400E-02 |
| Other-VS-Normal |
2.940400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.241210E-04 |
| Normal-vs-N1 |
5.88820000535506E-08 |
| N0-vs-N1 |
4.436300E-03 |
|
|
